Research
Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) and GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and improve glycemic control in patients with type 2 diabetes and obesity by acting on central satiety centers and peripheral metabolic pathways.
If you have T2DM or obesity, GLP-1 and dual GIP/GLP-1 agonists are highly effective treatments that work by mimicking natural gut hormones to reduce appetite and improve blood sugar. They are available as weekly injections or daily oral pills. Consult your doctor to see if one of these FDA-approved medications is right for you.
StrongSupportsVERY_HIGH confidence
Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases.
Why this rating
The paper cites multiple FDA-approved agents, phase 1-3 clinical trials, and extensive preclinical data.
Source
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu · Frontiers in Endocrinology · 2024
narrative_reviewCited 171×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →